-

Ingevity increases caprolactone monomer capacity at its Warrington, UK facility

NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity Corporation (NYSE:NGVT) today announced that it will increase caprolactone monomer capacity at its facility in Warrington, U.K., through a series of optimization projects over the next 12 months that are expected to increase Ingevity’s global monomer production capacity by over 20% and position the company to better meet demand and more effectively serve customers.

“We continue to experience growth in demand for the high-performance, sustainable solutions in our engineered polymers Capa® portfolio,” said Mike Smith, executive vice president and president, Performance Chemicals. “We are committed to continued investment in innovation, production and customer partnerships to meet the expanding requirements of customers in a variety of end-use markets.” Smith added this exciting news follows recent announcements that the company will open a new innovation center in Warrington at the end of 2021 and add polyol production capabilities at its DeRidder, Louisiana, facility in the second quarter of 2022.

“This capacity expansion in Warrington will better position Ingevity to meet increased global demand for our Capa derivative technologies, improve the reliability of monomer supply in the merchant market and enhance service for customers across the globe,” said Steve Hulme, Ingevity’s vice president, engineered polymers.

Ingevity: Purify, Protect and Enhance

Ingevity provides products and technologies that purify, protect and enhance the world around us. Through a team of talented and experienced people, we develop, manufacture and bring to market solutions that help customers solve complex problems and make the world more sustainable. We operate in two reporting segments: Performance Chemicals, which includes specialty chemicals and engineered polymers, and Performance Materials, which includes high-performance activated carbon. These products are used in a variety of demanding applications, including asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, publication inks, coatings, elastomers, bioplastics and automotive components that reduce gasoline vapor emissions. Headquartered in North Charleston, South Carolina, Ingevity operates from 25 locations around the world and employs approximately 1,850 people. The company is traded on the New York Stock Exchange (NYSE:NGVT). For more information visit www.ingevity.com.

Cautionary Statements About Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements generally include the words “will,” “plans,” “intends,” “targets,” “expects,” “outlook,” or similar expressions. Forward-looking statements may include, without limitation, capacity expansion plans, expected financial positions, results of operations and cash flows; financing plans; business strategies and expectations; operating plans; and the impact of COVID-19. Actual results could differ materially from the views expressed. Factors that could cause actual results to materially differ from those contained in the forward-looking statements, or that could cause other forward-looking statements to prove incorrect, include, without limitation, implementation delays, adverse effects from the COVID-19 pandemic; adverse effects of general economic and financial conditions; risks related to international sales and operations; and the other factors detailed from time to time in the reports we file with the SEC, including those described under "Risk Factors" in our Annual Report on Form 10-K, our Form 10-Q for the quarter ended March 31, 2021, and other periodic filings. These forward-looking statements speak only as of the date of this press release. Ingevity assumes no obligation to provide any revisions to, or update, any projections and forward-looking statements contained in this press release.

Contacts

Caroline Monahan
843-740-2068
caroline.monahan@ingevity.com

Investors:
Bill Hamilton
843-740-2138
investors@ingevity.com

Ingevity Corporation

NYSE:NGVT

Release Summary
Ingevity will increase caprolactone monomer capacity at its facility in Warrington, U.K., to support the growing global demand from customers.

Contacts

Caroline Monahan
843-740-2068
caroline.monahan@ingevity.com

Investors:
Bill Hamilton
843-740-2138
investors@ingevity.com

More News From Ingevity Corporation

Ingevity releases 2024 sustainability report, highlights product innovation and technologies for a sustainable future

NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity today published its 2024 Sustainability Report featuring the impact of the company’s transformative technologies and products....

Ingevity announces departure of Performance Materials segment president, Ed Woodcock

NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity today announced Ed Woodcock, executive vice president and president, Performance Materials, departed the company effective July 1, 2025....

Ingevity reports first quarter 2025 financial results

NORTH CHARLESTON, S.C.--(BUSINESS WIRE)--Ingevity Corporation (NYSE: NGVT) today reported its financial results for the first quarter of 2025....
Back to Newsroom